Dental Care Clinics in Turnersville, NJ Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 The Dayspring Center For Laser Dentistry Dentist Medicare: Not Enrolled in Medicare Practice Location: 188 Fries Mill Road, Suite E2, Turnersville, NJ 08012 Phone: 856-875-8400 Fax: 856-875-5329 |
Crown'd Dentistry Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 188 Fries Mill Rd Ste D3, Turnersville, NJ 08012 Phone: 856-352-5255 Fax: 856-352-5253 |
Cross Keys Family Dental Pa Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 3501 Route 42, Turnersville, NJ 08012 Phone: 732-914-1039 Fax: 732-914-8472 |
Frank Amato, Dmd, Pa Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 129 Johnson Rd, Suite 6, Turnersville, NJ 08012 Phone: 856-401-8500 Fax: 856-401-8509 |
Barry E Ettelson Dds Pa Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 900 Route 168 Ste I6, Washington Professional Campus, Turnersville, NJ 08012 Phone: 856-227-2554 Fax: 856-227-4066 |
News Archive
HEALTHPOINT provides donation to support 100 free AAWC patient memberships
HEALTHPOINT today announced it will provide a donation to the Association for the Advancement of Wound Care Patient Advocacy Campaign to support 100 free AAWC patient memberships. The AAWC initiative is to be formally launched today during the Opening Ceremony of the Spring 2010 Symposium on Advanced Wound Care, on April 17, 2010, from 2:15-3:00 PM at the Gaylord Palms Hotel and Convention Center in Orlando, FL.
Retrophin to acquire privately-held company, Kyalin Biosciences
Retrophin, Inc. today announced that it will acquire privately-held Kyalin Biosciences, Inc., an early-stage company based in San Diego, CA, that is developing therapies targeting the core symptoms of autism and related conditions.
FDA approval of OMONTYS triggers $50M milestone payment to Affymax
Affymax, Inc. today announced that it has received a $50 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize OMONTYS (peginesatide) Injection.
Salk scientists develop new way to find responders to lithium therapy
For roughly one-third of people diagnosed with bipolar disorder, lithium is a miracle drug, effectively treating both their mania and depression. But once someone is diagnosed, it can take up to a year to learn whether that person will be among the 30 percent who respond to lithium or the 70 percent who do not.
› Verified 2 days ago